Component
Inflammatory products in apigenin-glucuronide-treated RAW264.7 cells
Inflammatory products in apigenin-glucuronide-treated RAW264.7 cells
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
- experimental_condition
- LPS alone Apigenin 7-O-glucuronide plus LPS · Apigenin 7-O-glucuronide Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_condition
- LPS alone LPS challenge · Lipopolysaccharide Condition belongs to the full experimental contrast; do not separate a joint intervention.
- experimental_contrast
- {"intervention": "Apigenin 7-O-glucuronide plus LPS", "comparator": "LPS alone", "endpoint": "Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.", "effect_direction": "decrease", "combination": "joint", "conditions": [{"entity_slug": "apigenin-7-glucuronide", "state": "Apigenin 7-O-glucuronide plus LPS"}, {"entity_slug": "lipopolysaccharide", "state": "LPS challenge"}]} Explicit extracted experimental comparison; recorded from source.
- experimental_model
- Mouse macrophage cell line; exposure details unavailable in the accessed abstract.
- interpretation_status
- Recorded from source with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
- plain_language
- Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.
- primary_references
- Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k
- source_locator
- Reviewed reference api-glucuronide-activity; Do not assume conjugates are inert or assume intracellular parent regeneration; intracellular speciation was not established by this abstract.
Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 130–136
AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Mouse macrophage cell line; exposure details unavailable in the accessed abstract. · Recorded from source · Recorded from source
### api-glucuronide-activity Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells. Do not assume conjugates are inert or assume intracellular parent regeneration; intracellular speciation was not established by this abstract. Model and exposure: Mouse macrophage cell line; exposure details unavailable in the accessed abstract. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | 2016 | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.